#### JUBILANT PHARMA LIMITED (Company Registration No. 200506887H) (Incorporated in the Republic of Singapore) Registered office: 80 Robinson Road, #02-00, Singapore 068898

February 25, 2019

#### **Singapore Exchange Securities Trading Limited** 11 North Buona Vista Drive #06-07 The Metropolis Tower 2 Singapore 138589

Dear Sirs,

### Sub: Proposal to issue unsecured bonds under Regulation S of the U.S. Securities Act of 1933, as amended.

We wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. February 25, 2019, approved the proposal to launch an offering of unsecured bonds (the "**Notes**") under Regulation S of the U.S. Securities Act of 1933, as amended. The Notes are proposed to be (i) issued to institutional investors outside India and (ii) listed and quoted on the Official List of the Singapore Exchange Securities Trading Limited.

The Company proposes to undertake meetings with one or more potential international institutional investors located in different jurisdictions pursuant to the approval of the Board of Directors for the offering of the Notes as stated below:

Date of Meetings	Location of Meetings
February 26, 2019	Singapore
February 27, 2019	Hong Kong and London

The schedule of meetings may undergo change due to exigencies on the part of the investors or the Company.

A copy of the investor presentation to be shared with the investors during the meetings is attached herewith. Further, the investor presentation along with certain related additional information shall also be available on the website of the Company (www.jubilantpharma.com).

Upon completion of these investors meetings and the book building process, the Company is expected to price the issuance of the Notes. We will intimate the stock exchange upon completion of the pricing of the Notes once the Company has determined the final terms of such Notes, including the total amount of the securities proposed to be issued by way of the Notes.

The Company will provide further updates in this regard, if and when necessary.

We request you to take the same on record.

This notice is not for distribution in or into the United States. This notice is not an offer for sale of any securities in the United States or any jurisdiction. Securities may not be offered or sold in the United States or any jurisdiction absent registration or an exemption from registration under applicable laws and regulations. Any public offering of securities to be made in the United States would be made by means of a prospectus that would contain detailed information about the issuer, their management and their financial statements in compliance with all relevant laws. The issuer does not have any current intention to make any public offering of, or to register, any securities in the United States.

Thanking you,

4

Yours Faithfully, For Jubilant Plarma Limited

Arun Kumar Sharma Chief Financial Officer



# JUBILANT PHARMA

# Jubilant Pharma Limited Investor Presentation

February 2019

### Disclaimer

This presentation (the "Presentation", or the "document") has been prepared by Jubilant Pharma Limited (the "Company" or "JPL") for the recipient for the purpose of providing information on the Company. The contents of this Presentation are confidential and strictly for use by the recipient only. The Presentation shall not, in whole or in part, be disclosed without prior written consent of the Company. This Presentation must not be copied, reproduced, distributed, or otherwise disclosed or passed on to others, in whole or in part, by any means, in any form under any circumstances whatsoever at any time hereafter. In furnishing this document, neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, undertake any obligation to provide to the recipient (a) access to any additional information or to update this document, or (b) to correct any inaccuracies therein which may or may not become apparent.

This Presentation may contain statements about events and expectations that may be "forward-looking", including statements relating to future status, events, prospects or circumstances, including but not limited to statements about plans and objectives, outlook, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such forward looking statements are made based on management's current expectations or beliefs as well as assumptions made (in good faith) by, and information currently available to, the management. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from these forward-looking statements due to number of risks and uncertainties, including future changes or developments in the Company's business, its competitive environment, its ability to implement its strategies and initiatives, respond to industry changes and the political, economic, regulatory and social conditions in India. The Company may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

This Presentation does not constitute a prospectus, offering circular or offering memorandum or an offer or invitation or a solicitation of any offer to purchase or sell, any securities of the Company, and should not be considered or construed in any manner whatsoever as a recommendation that any person should subscribe for or purchase any of Company's securities. None of the projections, expectations, estimates or prospects in this Presentation should be construed as a forecast implying any indicative assurance or guarantee of future performance, nor that the assumptions on which such future projections, expectations, estimates, or prospects have been prepared are complete or comprehensive.

This Presentation utilizes information which has not been independently verified (including by opinion, anecdote and speculation) and which has been sourced from a variety of public sources and third parties. Neither the Company, nor its associates and affiliates, nor any of their respective officers, directors, advisors, makes any representation or warranty (expressly or impliedly) as to the accuracy, adequacy or completeness of this document or its contents or of any other oral or written information furnished or made available. The Company disclaims to the extent possible by law, all responsibility in relation to this Presentation.

This Presentation, is not a recommendation to invest, is not an investment advice, and, is prepared to provide background information for investors in relation to the Company. This Presentation does not purport to contain all information investors may require to evaluate an investment in the Company. In preparing the Presentation, the Company have not taken into account the particular investment objectives, financial situation or particular needs of investors. Before making an investment decision, an investor should independently consider whether an investment in the Company is appropriate in light of its particular investment needs, objectives and financial circumstances. An investor should conduct its own independent investigations, due diligence and analysis of the potential benefits and risks of any investment in the Company. An investor should seek professional advice, including tax advice before making an investment decision.

This Presentation contains certain non-IFRS measures, including EBITDA and EBITDA margin. The measures have been used by management as supplemental measures of the Company's performance and are not required by, or presented in accordance with, IFRS. Further, these non-IFRS measures are not measures of financial performance or liquidity under IFRS and should not be considered alternatives to result from operating activities, profit before tax, profit for the year or any other performance measure derived in accordance with IFRS or as an alternative to cash flow from operating activities. You should not consider these non-IFRS measures in isolation from, or as a substitute for, analysis of the financial condition or results of operations of the Group, as reported under IFRS.

This Presentation also contains certain statistical data and analyses (the "Statistical Information") which have been prepared in reliance upon information furnished by the Company and/or third party sources for which the Company has either obtained or is in the process of obtaining the necessary consents for use. Numerous assumptions were used in preparing the Statistical Information, which assumptions may or may not appear herein. As such, no assurance can be given as to the Statistical Information's accuracy, appropriateness or completeness in any particular context, nor as to whether the Statistical Information and/or the assumptions upon which they are based reflect present market conditions or future market performance. Moreover, any information from third party sources contained in these materials may not be used or relied upon by any other party, or for any other purpose, and may not, directly or indirectly, be reproduced, disseminated or quoted without the prior written consent of such third party.

This Presentation does not constitute or form a part of any offer to sell, offer to purchase, or a solicitation to sell or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction. No securities of or relating to the Company referred to herein have been, and will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state of the United States or any other jurisdiction and no such securities may be offered or sold in the United States absent registration under, or an applicable exemption from, the registration requirements of the Securities Act and the rules and regulations thereunder. No public offering of securities will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. Any offer of such securities will be made by means of an offering document that will contain detailed information about the Company and its subsidiaries, the securities, as well as the Company's financial statements.

This Presentation may not be taken or transmitted into the United States, Canada or Japan and are not for distribution, directly or indirectly, in or into the United States, Canada or Japan. The distribution of this Presentation in or from certain other jurisdictions may also be restricted or prohibited by law. Recipients are required to inform themselves of, and comply with, all restrictions or prohibitions in relevant jurisdictions. Neither the Company nor any other person shall have any liability to any person in relation to the distribution or possession of this document or copies thereof in or from any jurisdiction where the distribution of such a document is prohibited or requires special authorization or any regulatory consent or approval. By accepting this document the recipient has agreed, upon request, to return promptly all material received from the Company without retaining any copies.

By accepting this Presentation, the recipient agrees that this Presentation, and any other oral or written information made available in relation the Company, is strictly confidential and shall not be copied, published, distributed or transmitted to any person, in whole or in part, by any means, in any form under any circumstances whatsoever and that the recipient has further agreed, upon request, to return promptly all material received from the Company without retaining any copies. The recipient further represents and warrants that it is lawfully able to receive this Presentation under the laws of the jurisdiction in which it is located and / or any other applicable laws, and that it will not reproduce, publish, disclose redistribute or transmit this Presentation.


Pharma

# Agenda

- Jubilant Pharma Limited (JPL) overview
- Credit highlights
- Appendix



# Jubilant Pharma – A Global Integrated Pharmaceuticals Company




- (1) Calculated as % of revenue from operations
- (2) Calculated as % of total revenue
- (3) Excluding GPOs but including customers purchasing goods and services through such GPOs
- (4) For 9 months ended December 31, 2018
- (5) As of December 31, 2018

3



# **Evolution of Jubilant Pharma**



Continued Focus on Specialty Pharmaceuticals – Radiopharmaceuticals, Contract Manufacturing and Allergy Therapy Products

4

# **Radiopharmaceuticals Business**

Industry Overview <sup>(1)</sup>	<ul> <li>Radiopharmaceuticals Industry in North America is US\$2.4bn, expected to grow at CAGR of 6.2% to reach US\$3.5bn by 2023</li> <li>Oncology and cardiology diagnosis accounted for 69.4% of the industry in 2017</li> <li>Increase of cardiovascular, cancerous and neurological diseases are likely to drive molecular imaging procedures</li> </ul>
Business Overview	<ul> <li>Specializes in cardiology, pulmonology, oncology and endocrinology as well as bone, brain and renal imaging</li> <li>Supplies 14 diagnostic and therapeutic radiopharmaceutical products to 18 countries</li> <li><u>#3 radiopharmaceutical manufacturer</u> in nuclear medicine industry for the US based on revenue<sup>(1)</sup></li> <li>Customers include 3<sup>rd</sup> party commercial radiopharmacy networks, our radiopharmacies, hospitals, standalone imaging centers and cardiologists</li> <li>Long-term contracts in place in the US</li> <li>USFDA approved manufacturing facility at Kirkland, Montreal</li> </ul>
Products	<ul> <li>DRAXIMAGE® MAA for lung perfusion imaging (sole supplier in the US with 100% market share<sup>(1)</sup>)</li> <li>DRAXIMAGE® DTPA for lung ventilation and renal imaging (sole supplier in the US with 100% market share<sup>(1)</sup>)</li> <li>HICON® Sodium Iodine-131 solution for thyroid disease and thyroid cancer management (one of the only three manufacturers of I-131 (Thyroid) globally<sup>(1)</sup>)</li> <li>Drax Exametazime™ (505 (b)(2)product) for intra-abdominal infection and inflammatory bowel disease</li> <li>RUBY-FILL® Rubidium Rb82 Generator and Elution System™ (505(b)(2)products) for myocardial perfusion imaging with PET</li> <li>Planning to file NDA for I-131 mIBG (currently undergoing Phase II and Phase III clinical trials in the US) and 505(b)(2) for 8 other products</li> </ul>
Strategy	<ul> <li>Achieve market leadership in the nuclear medicine industry</li> <li>Increase market share of RUBY-FILL® Rubidium Generator and Elution System<sup>™</sup> - cardiac PET imaging</li> <li>Leverage leadership in existing products</li> <li>Expand product portfolio through launch of niche and differentiated products</li> </ul>

#### JUBILANT PHARMA

Radiopharmaceuticals 47.6%

# **Radiopharmacy Business**

#2 commercial radiopharmacy network<sup>(1)</sup> in the US, operated under the "Triad Isotope" brand  $\geq$ 

- Facilities also include three operational cyclotrons
- Multi-year agreements with GPOs in place  $\geq$



Over 50 radiopharmacies spread across 22 states

Radiopharmaceuticals 47.6%



750+ employees

c.3m+ doses delivered annually



c.1,700 customers across national GPOs, regional Networks, local hospitals and physician groups



Strong relationships with major national GPOs

#### Build the nation's premier radiopharmacy network

- Optimizing coverage of radiopharmacy network through further additions and improvements or consolidation  $\geq$
- Establish new distribution channels through collaboration and contractual arrangements with strategic partners  $\geq$
- $\geq$ Geographic expansion in the US and Canada by increasing brand recognition among hospital networks




Global and US Generic Pharmaceutical Industry

(1)


# **CMO Business – Sterile Injectables and Non-Sterile Products**








# **Allergy Therapy Business**





# **Solid Dosage Formulations Business**



- One of the market leaders in select key products in the US<sup>(1)</sup>
  - > Benefit from backward integration into API business supported by in-house R&D facilities
  - > Manufacturing facility at Salisbury, US (USFDA) and Roorkee, India (USFDA, PMDA Japan, ANVISA Brazil and MCC South Africa certifications)

	Product	US Market Share <sup>(1)</sup>	US Rank <sup>(1)</sup>	
	Prochlorperazine	c.52%	#1	
	Terazosin	c.52%	#1	
	Methylprednisolone	c.38%	#1	
Products	Olanzapine ODT	c.22%	#2	
	Prednisone	c.9%	#3	
	Donepezil	c.8%	#4	
	Pantoprazole	c.13%	#4	

- #1 player in 3 products with over 35% share in each of the three products
- Amongst top 3 players in another 2 products
- Amongst top 5 players in another 2 products


> Aim is to be the first to enter and last to exit using our chemistry and R&D capabilities and manufacturing expertise to drive growth

> Focus on investment in R&D in order to increase our ANDA filings and approvals

Focus on cost leadership with increased integration of in-house APIs

- > Expand business into emerging markets by leveraging existing US filings
- > Increasing solid dosage formulations capacity at Roorkee facility

9 (1) According to Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic Pharmaceutical Industry



**Business** 

**Overview** 

Strategy

(3) Only includes prescription drugs




### **APIs Business**

			Global Market Size : Synthetic API <sup>(1)</sup>						
				CAGR (2018-22): 6.	.7%				
Industry Overview <sup>(1)</sup>	Global Synthetic API market is U	5\$115bn in 2018 and is expected to grow at a	115	123	131	129	149		
	CAGR of 6.7% from 2018 to 2022		<b>E</b> 48	51	53	46	62		
	> 53% of outsourced API market is		(uq\$SN) 48	72	78	83	87		
			2018E	2019F	2020F	2021F Outsourced	2022F		
						outsourcea			
	- · · ·	market leadership in select key API products <sup>(1</sup>							
	· · · ·	io is in lifestyle driven therapeutic areas such a	as CVS and CNS,	catering to a	n increasing inc	idence of lifesty	le-related		
Business	medical conditions or non-comm								
		c.60% of API sales are to regulated markets							
Overview									
Overview	Sartans continue to be a key focular	us area							
Overview	Sartans continue to be a key focular		RIS Mexico and	Brazil ANVISA	certifications) <sup>(</sup>	(2)			
Overview	Sartans continue to be a key focular	us area	RIS Mexico and Product			(2) lobal Market Sh	are <sup>(1)</sup>		
Overview	<ul> <li>Sartans continue to be a key foct</li> <li>API facility at Nanjangud, Karnat</li> </ul>	us area aka (USFDA, PMDA Japan, KFDA Korea, COFEP					are <sup>(1)</sup>		
	<ul> <li>Sartans continue to be a key foct</li> <li>API facility at Nanjangud, Karnat</li> </ul> Product	us area aka (USFDA, PMDA Japan, KFDA Korea, COFEP <b>Global Market Share<sup>(1)</sup></b>	Product	e		lobal Market Sh	are <sup>(1)</sup>		
Products <sup>(1)</sup>	<ul> <li>Sartans continue to be a key foct</li> <li>API facility at Nanjangud, Karnat</li> <li>Product</li> <li>Risperidone</li> </ul>	us area aka (USFDA, PMDA Japan, KFDA Korea, COFEP <b>Global Market Share<sup>(1)</sup></b> c.33%	<b>Product</b> Meclizin	e am		lobal Market Sh c.20%	are <sup>(1)</sup>		
	<ul> <li>Sartans continue to be a key foct</li> <li>API facility at Nanjangud, Karnat</li> <li>Product         <ul> <li>Risperidone</li> <li>Oxcarbazepine</li> </ul> </li> </ul>	us area aka (USFDA, PMDA Japan, KFDA Korea, COFEP Global Market Share <sup>(1)</sup> c.33% c.30%	<b>Product</b> Meclizin Citalopr	e am		lobal Market Sh c.20% c.18%	are <sup>(1)</sup>		
	<ul> <li>Sartans continue to be a key foct</li> <li>API facility at Nanjangud, Karnat</li> <li>Product</li> <li>Risperidone</li> <li>Oxcarbazepine</li> <li>Carbamazepine</li> </ul>	us area aka (USFDA, PMDA Japan, KFDA Korea, COFEP Global Market Share <sup>(1)</sup> c.33% c.30% c.20% c.20%	<b>Product</b> Meclizin Citalopr	e am		lobal Market Sh c.20% c.18%	are <sup>(1)</sup>		
	<ul> <li>Sartans continue to be a key foct</li> <li>API facility at Nanjangud, Karnat</li> <li>Product         <ul> <li>Risperidone</li> <li>Oxcarbazepine</li> <li>Carbamazepine</li> <li>Pinaverium</li> </ul> </li> <li>Continue to be a preferred supp</li> </ul>	us area aka (USFDA, PMDA Japan, KFDA Korea, COFEP Global Market Share <sup>(1)</sup> c.33% c.30% c.20% c.20%	<b>Product</b> Meclizin Citalopr Donepe	e am zil		lobal Market Sh c.20% c.18%	are <sup>(1)</sup>		
	<ul> <li>Sartans continue to be a key foct</li> <li>API facility at Nanjangud, Karnat</li> <li>Product         <ul> <li>Risperidone</li> <li>Oxcarbazepine</li> <li>Carbamazepine</li> <li>Pinaverium</li> </ul> </li> <li>Continue to be a preferred supp</li> <li>Focus on product selection, new</li> </ul>	us area aka (USFDA, PMDA Japan, KFDA Korea, COFEP Global Market Share <sup>(1)</sup> c.33% c.30% c.20% c.20% ier to our customers	Product Meclizin Citalopr Doneper	e am zil ducts	G	lobal Market Sh c.20% c.18% c.16%			
Products <sup>(1)</sup>	<ul> <li>Sartans continue to be a key foct</li> <li>API facility at Nanjangud, Karnat</li> <li>Product         <ul> <li>Risperidone</li> <li>Oxcarbazepine</li> <li>Carbamazepine</li> <li>Pinaverium</li> </ul> </li> <li>Continue to be a preferred supp</li> <li>Focus on product selection, new</li> <li>Well differentiated strategy of p sustainable growth</li> </ul>	us area aka (USFDA, PMDA Japan, KFDA Korea, COFEP Global Market Share <sup>(1)</sup> c.33% c.30% c.20% c.20% lier to our customers product launches and increasing market share	Product Meclizin Citalopr Doneped	e am zil ducts r highly capab	Gi	lobal Market Sh c.20% c.18% c.16%			

(1) According to Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic Pharmaceutical Industry



# High-Quality, World-Class Global Manufacturing Footprint



4 USFDA approved manufacturing facilities in North America and 2 USFDA approved manufacturing facilities in India



# Agenda

- Jubilant Pharma Limited (JPL) overview
- Credit highlights
- Appendix



# **Jubilant Pharma: Credit Highlights**





### Leading Market Position Across Business Lines, with High Barriers To Entry For Specialty Pharmaceuticals

	Specialty Pharmaceuticals	
	Highlights	Entry Barriers
Radio pharmaceuticals	<ul> <li>#3 radiopharmaceuticals manufacturer for the US<sup>(1)(2)</sup></li> <li>#2 commercial radiopharmacy network in the US<sup>(1)(3)</sup></li> <li>Specialists in lung, thyroid, bone and cardiac imaging products         <ul> <li>Sole supplier in the US in MAA and DTPA<sup>(1)</sup></li> <li>One of the only three manufacturers of I-131 globally<sup>(1)</sup></li> <li>Received two 505(b)(2) approvals for RUBY-FILL<sup>®</sup> and Drax Exametazime<sup>T</sup></li> </ul> </li> </ul>	<ul> <li>Extensive regulatory and licensing requirements</li> <li>Capital intensive nature of the business</li> <li>Vertical Integration with commercial radiopharmacy business</li> </ul>
СМО	<ul> <li>Serves 7 out of the top 20 pharmaceutical companies globally based on revenue<sup>(1)</sup></li> <li>Deep and long-term relationships with our top 10 customers         <ul> <li>At least 10 years of business relationships with 6 of our top 10 customers<sup>(4)</sup></li> </ul> </li> </ul>	<ul> <li>Limited number of manufacturers with the requisite know-how for sterile injectables</li> <li>Proximity to customers</li> <li>Technical expertise required to develop products, obtain licensing and regulatory approvals</li> </ul>
Allergy Therapy Products	<ul> <li>One of the top #3 players in the allergenic extract market in the US<sup>(1)</sup></li> <li>Product range of 200+ different allergenic extracts, six insect venom products and exclusive skin diagnostic testing devices</li> <li>Sole producer and supplier of venom products in the US<sup>(1)</sup></li> </ul>	<ul> <li>Biotechnology products with grandfather status; new products require an NDA</li> <li>Niche US allergen extract market</li> </ul>
	Generics & APIs	
Solid Dosage Formulations	<ul> <li>54 products across the US, Europe, Canada, Australia and the rest of the world<sup>4</sup></li> <li>#1 player in 3 products with over 35% share in each of the three products</li> <li>Amongst top 3 players in another 2 products</li> <li>Amongst top 5 players in another 2 products</li> </ul>	<ul> <li>(4)</li> <li>APIs</li> <li>✓ One of the market leaders in the US for several key API products<sup>(1)</sup></li> <li>✓ Risperidone (global market share o c.33%)</li> <li>✓ Oxcarbazepine (global market shar at c.30%)</li> <li>✓ Carbamazepine (global market share at c.20%)</li> <li>and others</li> </ul>

14


(1) According to Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic Pharmaceutical Industry; (2) As of 2017 revenue; (3) As of September 2018; (4) As of December 31, 2018

**UBILAN** 

PHARMA

# Oiverse Sources of Revenue with a De-risked Business Model

- ✓ Jubilant Pharma's de-risked business model benefits from its diversified product offerings, product sourcing capabilities as well as a broad customer base with a global manufacturing and distribution footprint
- ✓ Presence across geographic locations enables Jubilant Pharma to capture different market segments



IUBILANI

contribution to total revenue<sup>(3)</sup>

15 (1) As at December 31, 2018

(2) Excluding GPOs but including customers purchasing goods and services through such GPOs


(3) Total revenue from operation for the financial year ended March 31, 2018 and 9 months ended December 31, 2018 (9MFY19)


# Strong Product Pipeline with Deep R&D Capabilities

#### Strong R&D Capabilities...

- Capabilities demonstrated by specialized and niche product filings
- Dedicated team of 400+ R&D professionals
- R&D centers located in India and North America

	Resulting in Strong Product Pipeline					
		Active Patents	Current Products and Pipeline			
Specialty Pharmaceuticals	Radiopharmaceuticals	123	<ul> <li>✓ Focused on high value niche products with diagnostic and/or therapeutic uses</li> <li>✓ Received 505(b)(2) approvals for RUBY-FILL<sup>®</sup>, Drax Exametazime<sup>™</sup></li> <li>✓ Planning to file NDA for I-131 mIBG and 505(b)(2) for 8 other products</li> </ul>			
Specialty P	Allergy Therapy Products	1	<ul> <li>Plan to register with USDA venom products and allergenic extracts for use in animals</li> </ul>			
and APIs	Solid Dosage Formulations	5	✓ Strong pipeline in Generics segment; 96 ANDA filings in the US, of which 35 are pending approval			
Generics and	APIs	19	✓ Strong pipeline in APIs segment; 94 DMF filings in the US			






16 Note: All data is as of December 31, 2018 (1) Product filings across geographies may pertain to overlapping products in the pipeline



### Global Competitive Edge due to Integrated and Efficient Manufacturing Operations



#### ...Supported by Six Manufacturing Facilities

Regulatory Agency <sup>(2)</sup>	Montreal, Canada (JDI)	Montreal, Canada (CMO)	Spokane, USA (CMO & Allergy Therapy)	USA (Solid Dosage	Roorkee India (Solid Dosage Formulations)	Nanjangud India (APIs)
USFDA	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$
Health Canada	$\checkmark$	$\checkmark$			$\checkmark$	$\checkmark$
PMDA Japan			$\checkmark$		$\checkmark$	$\checkmark$
India SLA / CDSCO					$\checkmark$	
ANVISA Brazil		$\checkmark$				$\checkmark$
T.C. Sağlık Bakanlığı Turkey			$\checkmark$			
COFEPRIS Mexico						$\checkmark$

- Plants operated in accordance with cGMP and/or other applicable requirements
- Team of 700+ quality control employees, 60+ regulatory employees and 50+ technical services employees
- ✓ All facilities have been inspected by USFDA in the last 18 months

(2) All dates/green ticks convey that the particular facility has been inspected by the respective agencies. In the case of USFDA, the dates pertain to the last inspection dates




### Demonstrated Financial Track Record with Strong Revenue Growth...

- Revenue from operations increased by 34.4%, in FY18 compared to FY17 while revenue from operations for 9MFY19 witnessed a 31.9% growth over the previous period
  - EBITDA increased by 49.3% in 9MFY19 compared to 9MFY18

 $\checkmark$ 

 $\checkmark$ 

- Increase in revenue and EBITDA attributable to increasing share of Specialty Pharmaceuticals in the segment mix
  - Specialty Pharmaceuticals business contribution to revenue increased from c.54% in FY17 to c.69% in 9MFY19
  - ✓ Specialty Pharmaceuticals business contribution to EBITDA increased from 68% in FY17 to 74% in 9MFY19
  - Focused on leveraging free cash flows generated from our operations to further strengthen ability to grow



**Revenue from Operations** 

Specialty Pharmaceuticals Generics & APIs

**EBITDA by Segment** 


Growth: 49.3% Growth: 9.0% 155<sup>(1)</sup> 151<sup>(1)</sup> (US\$m) 139<sup>(1)</sup> **104**<sup>(1)</sup> 124 101 138 95 47 44 26 18 FY17 FY18 **9MFY18 9MFY19** Specialty Pharmaceuticals Generics & APIs EBITDA Margins<sup>(2)</sup> FY17 FY18 9MFY18 9MFY19 Specialty Pharmaceuticals 40.8% 33.7% 34.4% 31.9% **Generics & APIs** 21.9% 12.3% 12.1% 25.2% 30.2% Overall 24.5% 24.4% 27.6%

#### Revenue by Segment



■ APIs ■ Formulations ■ Allergy Therapy ■ CMO ■ Radiopharmaceuticals

#### Net Income



Note: All financials include contribution from radiopharmacies (Triad Isotopes) from the period starting September 1, 2017

(1) Please note that the overall EBITDA includes unallocated depreciation and unallocated corporate expenses which are not included in Segment EBITDA. These amount to US\$9m in FY17, US\$12m in FY18, US\$9m in 9MFY18


and US\$12m in 9MFY19

18

- (2) Calculate as % of revenue from operations
- (3) Calculated as % of total revenue



# Image: Image:




19 Note: All financials include contribution from radiopharmacies (Triad Isotopes) from the period starting September 1, 2017

- (1) Based on annualised 9MFY19 financials
- (2) Net cash generated from operating activities
- (3) Working Capital = Current Assets excluding Cash and Cash Equivalents Current Liabilities excluding Loans and Borrowings



### Strong Acquisitions and Integration Capabilities with a Proven Track Record





### Highly Qualified, Experienced and Dedicated Board and Management Team

Promoters				
<b>Shyam S. Bhartia</b> <i>Chairman and</i> <i>Managing</i> <i>Director</i>	<ul> <li>Over 39 years of experience in the pharmaceuticals and specialty chemicals, food, oil &amp; gas and aerospace sectors</li> <li>A fellow member of the Institute of Cost Accountants of India</li> </ul>			
<b>Hari S. Bhartia</b> Co-Chairman & Non-Executive Director	<ul> <li>Over 33 years of experience in the pharmaceuticals and specialty chemicals, food, oil &amp; gas and aerospace sectors</li> <li>B.Tech (Chemical Engineering, Indian Institute of Technology, Delhi)</li> </ul>			
	Non-Executive Director			
<b>R. Sankaraiah</b> Non-Executive Director	<ul> <li>✓ Over 30 years of experience in M&amp;A, fund raising, accounting, taxation, etc.</li> <li>✓ Holds a bachelor's degree in science and a fellow member of the Institute of Chartered Accountants of India (ICAI)</li> </ul>			
	Senior Management			
<b>Pramod Yadav</b> Director and Chief Executive Officer	<ul> <li>Over 30 years of industry experience</li> <li>Holds a bachelor's degree from the Institute of Chemical Technology and a Masters in Marketing Management from Jamnalal Bajaj Institute of Management, Mumbai</li> </ul>			
<b>Arun Sharma</b> Chief Financial Officer	<ul> <li>Over 25 years of experience in strategic planning, acquisition finance, fund raising, etc.</li> <li>Holds a bachelor's degree in science and a member of the Institute of Chartered Accountants of India (ICAI)</li> </ul>			
<b>Mitchell Guss</b> Vice President (Legal)	<ul> <li>Over 30 years of legal experience</li> <li>A member of the New York State Bar and holds a Limited In House Corporate License in the State of Pennsylvania</li> </ul>			

Independent Directors				
Suresh Kumar Lead Independent Non-Executive Director	<ul> <li>Has been a Member of Sanofi's Executive Committee and spearheaded exports and FDI initiatives in the Obama Administration</li> <li>Holds an Economics degree and Masters in Management</li> </ul>			
<b>Fang Ai Lian</b> Independent Non- Executive Director	<ul> <li>Worked with Ernst &amp; Young (EY) for over 30 years and retired as Chairman of EY, Singapore in 2008</li> <li>A fellow of the Institute of Chartered Accountants in England and Wales and a fellow of the Institute of Singapore Chartered Accountants</li> </ul>			
<b>Arun Duggal</b> Independent Non- Executive Director	<ul> <li>Long and distinguished career of 26 years with Bank of America. Advised various companies, private equity firms and financial institutions on financial strategy, M&amp;A and capital raising</li> <li>Holds bachelor's degree in Mech. Engineering from IIT and post graduate Diploma in Business Admn. from IIM</li> </ul>			
<b>Tarun Kataria</b> Independent Non- Executive Director	<ul> <li>Over 25 years of experience in corporate finance, M&amp;A, capital markets and IPOs</li> <li>An MBA from The Wharton School, U.S and is also a Chartered Accountant from the Institute of Chartered Accountants of India (ICAI)</li> </ul>			

- Promoters continue to play an active role in driving the long term strategy for the business
- Distinguished Board of Directors with an average of 30 years of industry experience
- Senior management team has an average of 20 years of pharma industry experience


21

# Agenda

- Jubilant Pharma Limited (JPL) overview
- Credit highlights
- Appendix



### **Corporate Structure**



JUBILANT PHARMA

# **Summary Income Statement**

(US\$m, unless stated)	FY17	FY18	9MFY18	9MFY19
Revenue from operations	461	619	427	563
Other income	1	2	0	7
Total revenue	461	621	427	569
Growth (%)	5.0%	34.6%	   –	33.3%
Cost of materials consumed	(105)	(160)	(110)	(151)
Purchases of stock-in-trade	(8)	(11)	(8)	(9)
Changes in inventories of finished goods, stock-in-trade and work-in progress	10	2	7 	13
Employee benefits expense	(132)	(180)	(126)	(160)
Other expenses	(88)	(121)	(86)	(107)
EBITDA	139	151	104	155
Margin (%) <sup>(1)</sup>	30.2%	24.5%	24.4%	27.6%
Depreciation, amortization and impairment	(31)	(56)	(26)	(30)
Result from operating activities (EBIT)	108	96	78	125
Margin (%) <sup>(1)</sup>	23.4%	15.5%	18.3%	22.3%
Net finance costs	(35)	(23)	(17)	(15)
Profit before tax	73	73	61	110
Income tax expense	(23)	(24)	(18)	(33)
Profit for the year (net income)	50	49	44	77
Margin (%) <sup>(2)</sup>	10.9%	7.9%	10.2%	13.5%

JUBILANT PHARMA



(1) Calculated as % of revenue from operations

(2) Calculated as % of total revenue

# **Summary Balance Sheet**

	As	at
(US\$m, unless stated)	31-Mar-2018	31-Dec-2018
Assets		
Non-current assets		
Property, plant and equipment	278	281
Goodwill	169	164
Other assets <sup>(1)</sup>	200	188
Total non-current assets	647	633
Current assets		
nventories	112	131
Frade receivables	106	101
Other financial assets	9	9
ncome tax assets	1	0
Other current assets	23	28
Cash and cash equivalents	27	60
Fotal current assets	278	329
Fotal assets	925	962
Equity and liabilities		
<u>Equity</u>		
Equity share capital	327	327
Foreign currency translation reserve	(22)	(55)
Other components of equity <sup>(2)</sup>	80	148
Total equity attributable to owners of the Company	384	420
<u>Non-current liabilities</u>		
oans and borrowings	394	400
Other non-current liabilities <sup>(3)</sup>	24	26
Fotal non-current liabilities	418	426
Current liabilities		
oans and borrowings	14	10
mployee benefits	17	16
rade payables	62	65
Other current liabilities <sup>(4)</sup>	29	24
Fotal current liabilities	123	116
Total equity and liabilities	925	962

Note: Following items have been combined together:

(1) Other assets = Other intangible assets + Investments + Other financial assets + Income tax assets + Deferred tax assets (net) + Other non-current assets
 (2) Other components of equity = Merger reserve + Retained earnings +Other components of equity
 (3) Other non-current liabilities = Employee benefits + Deferred tax liabilities (net) + Provisions + Other non-current liabilities
 (4) Other current liabilities = Other financial liabilities + Income tax liabilities + Other current liabilities



# **Summary Cash Flow Statement**

(US\$m, unless stated)	FY17	FY18	9MFY18	9MFY19
Operating cash flow before working capital changes	140	151	104	152
Cash generated from operations	148	144	110	130
Net cash generated from operating activities	129	116	83	99
Net cash used in investing activities	(88)	(67)	(53)	(34)
Net cash used in financing activities	(18)	(70)	(51)	(31)
Cash and cash equivalents at the end of the year/period	48	27	29	60



# **Abbreviations**

AIT	Allergen Immunotherapy
ANDA	Abbreviated New Drug Application
ΑΡΙ	Active Pharmaceutical Ingredient
АТР	Allergy Therapy Business
CDMO	Contract Development and Manufacturing
СМО	Contract Manufacturing Operations
CNS	Central Nervous System
CVS	Cardio-Vascular System
DMF	Drug Master File
DTPA	Diethylene Triamine Penta Acetic Acid

GPO	Group Purchasing Organization
I-131	lodine-131
IND	Investigational New Drug
MAA	Macro Aggregates of Albumin
MHRA	Medicines and Healthcare Products Regulatory Agency (United Kingdom)
NDA	New Drug Application
PET	Position Emission Tomography
PMDA	Pharmaceuticals and Medical Devices Agency (Japan)
USDA	The United States Department of Agriculture
USFDA	United States Food and Drug Administration





# JUBILANT PHARMA

# **Thank You**

February 2019